The provided text consists of excerpts from the Form 10-Q Quarterly Report for Eli Lilly and Company, covering the period ended September 30, 2025. This document offers a detailed look at the company's financial performance and condition, including the Consolidated Condensed Statements of Operations, Balance Sheets, and Cash Flows, with accompanying notes to the financial statements. Additionally, the report contains an executive overview discussing financial results, updates to the clinical development pipeline (highlighting key compounds like tirzepatide and orforglipron), and a discussion of market trends affecting pharmaceutical pricing, reimbursement, and access, alongside a section on forward-looking statements outlining potential risks. Significant financial details include a major increase in revenue and net income driven primarily by volume growth of key products like Mounjaro and Zepbound, and disclosures regarding recent acquisitions and legal contingencies.